Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

Nachrichtenagentur: news aktuell
14.09.2020, 02:10  |  221   |   |   
Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN
Bladder 100 study of BAVENCIO®* assess efficacy across subgroups,
patient-reported outcomes and exploratory biomarkers in advanced urothelial

· Overall efficacy data, and analyses of brain metastases and HRQoL for
tepotinib? from largest ongoing study in NSCLC harboring MET ex14 skipping

· Long-term follow-up data for novel bifunctional fusion protein targeting
TGF-?/PD-L1, bintrafusp alfa?, in NSCLC and BTC demonstrate continued durability
of response

Not intended for UK- US- or Canada-based media

Merck, a leading science and technology company, today announced more than 30
abstracts will be presented at the European Society for Medical Oncology (ESMO)
Virtual Congress 2020 from September 19-21. The abstracts span the Company's
clinical program in oncology across several innovative modalities and mechanisms
that have the potential to advance treatment across a range of tumor types
including biliary tract, lung and urothelial (bladder) cancers.

"Our oncology ambition is to discover innovative therapies with transformative
results. The data being presented in urothelial cancer demonstrate this approach
in action, where we are seeing promising results for a new first-line
maintenance therapeutic option with BAVENCIO® in this form of cancer," said
Luciano Rossetti, Global Head of Research & Development for the Biopharma
business of Merck. "In addition, long-term follow-up data in advanced lung
cancer from two of our in-house developed mechanisms-our oral MET inhibitor,
tepotinib, and our first-in-class bifunctional fusion protein immunotherapy
targeting TGF-?/PD-L1, bintrafusp alfa-continue to show sustained impact in one
of the leading causes of cancer mortality."

Key data highlights at ESMO

Avelumab (BAVENCIO®)

Phase III JAVELIN Bladder 100 (Presentations #699O; 704MO; 745P). Primary
results from the JAVELIN Bladder 100 study demonstrated an overall survival (OS)
benefit for BAVENCIO vs. best supportive care in the first-line maintenance
treatment of advanced urothelial carcinoma, making BAVENCIO the first and only
immunotherapy to significantly prolong OS in this setting. Three new abstracts
from the JAVELIN Bladder 100 study will be presented at ESMO:

- An oral presentation during the Proffered Paper 1 - GU, non-prostate session
scheduled on September 19, 2020 at 5:28pm-5:40pm CEST/11:28am-11:40am EDT,
will highlight associations between clinical outcomes and exploratory
biomarkers (Presentation #699O)
- Two other abstracts provide more information on prespecified subgroup
analyses, as well as patient-reported outcomes.
Seite 1 von 6
Merck Aktie jetzt ab 0€ handeln - auf

Diesen Artikel teilen

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors